The US FDA has just approved the home administration of Teva’s Synribo (omacetaxine mepesuccinate). Physicians who treat adults with chronic or accelerated phase Chronic Myeloid Leukemia (CML) can now administer Synribo therapy in the patient’s own home.
http://www.globes.co.il/en/article-teva-receives-fda-approval-for-leukemia-treatment-1000936451